Trial · NCT06405100
Efficacy and Safety of Tacrolimus in Combination With Ripertamab in the Initial Treatment of Patients With MCD
NCT06405100, Phase 3, Not yet recruiting, Air Force Military Medical University, China
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Efficacy and Safety of Tacrolimus in Combination With Ripertamab in the Initial Treatment of Patients With MCD. Trials, record NCT06405100. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06405100
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy and Safety of Tacrolimus in Combination With Ripertamab in the Initial Treatment of Patients With MCD
- NCT number
- NCT06405100
- Status
- Not yet recruiting
- Phases
- Phase 3
- Enrollment
- 81 participants, estimated
- Lead sponsor
- Air Force Military Medical University, China
- Conditions
- Minimal Change Disease
- Interventions
- Supportive care+Prednisone, Supportive care+Tacrolimus+Ripertamab, Supportive care+Ripertamab
- First posted
- 2024-05-08
- Last updated
- 2024-05-08
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Relapse rate at 24 months | Up to 24 months after enrollment | Relapse: Proteinuria\>3.5g/d or PCR\>3500mg/g after complete remission has been achieved. |
| Secondary | Relapse rate at 12/18 months | Up to 18 months after enrollment | The relapse rates of MCD patients at 12 months and 18 months were observed |
| Secondary | Partial or complete remission at 2/6/12/24 months | Up to 24 months after enrollment | Partial remission: Reduction of proteinuria to 0.3-3.5g/d, or PCR 300-3500mg/g and a decrease \>50% from baseline Complete remission: Reduction of proteinuria to \<0.3g/d or PCR\<300mg/g |
| Secondary | The time from the start of treatment to achieve complete remission | Up to 24 months after enrollment | The time it takes for patients with MCD to reach a state of complete remission needs to be observed |
| Secondary | The time from clinical complete remission to replase | Up to 24 months after enrollment | |
| Secondary | Safety-adverse events | The time from randomization until the occurrence of such adverse events, up to 24 months | Creatinine levels doubled from baseline; an increase ≥30% from eGFR baseline; ESRD; adverse events; drug-related adverse events, and abnormal clinical manifestations |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06405100
GET https://conductscience.org/api/trials/v1/NCT06405100/registered